1

Fareed Zakaria: Will US maintain its innovation lead in new global landscape?

CNN host Fareed Zakaria said yesterday that despite the world’s current economic and political difficulties,   he is optimistic about the future  but that it is by no means clear “who will be winners and the losers”  in what he called a “new global landscape.”

In a keynote talk at the Biotechnology Industry Organization International Convention in Boston,  Zakaria said, that the world is currently “extraordinarily  peaceful” compared with previous decade and that it is quite “unified, with a global economic system, interactive communications and technology and greater computing power than ever before.  (For example,  the cell phone has more computing power than did the Apollo spacecraft capsule in 1969. ” It could go to the moon, he said, but it could not tweet,”  he quipped. )

In the past, he said, the US has always been able to emerge from  economic difficulties  due to its tremendous capacity to innovate–and in the second half of the twentieth century, maintained a substantial economic and innovative edge over other nations.  But, he said, “we forget that at other times, other countries have  had the edge.”    He asked, “Will the US  maintain its edge?”

Zakaria outlined what he called three distinct historical  phases or causes that, he said, account for the US’  “extraordinary” lead:

(1) During World War II, the forces of destruction had a huge spillover effect.  Germany, a major US competitor, was “leveled to the ground” and England was bankrupted.

(2) During the Cold War, fears of losing out to the USSR in the 1950s  led the US government to make double the investment in US companies than it is making now;  government purchases of US computers and components accounted for the lion’s share of profits for those companies, until the cost curve began to decline. What is more, the government invested heavily in higher education, so that citizens could obtain the world’s finest education in public universities” without paying a cent”

(3) “The third pillar was Jews ” he said. “If  Hitler had not made the morally reprehensible to target Jews, the US would not have had the influx of scientists who created the bomb, transformed theoretical physics and gave the US a 30-year lead.”

What this shows, he said,  is that America’s propensity of innovate is “not due to DNA,” but rather, that there are specific historical reasons why the US took a commanding lead.

Today, he said, there is a new global landscape  in which it is possible for smaller nations– such as Denmark, where  the Global company Novo Nordisk, known for its diabetes treatments,  was founded–  to be at the leading edge in certain technologies.

What is more, Zakaria pointed out,  innovation does not necessarily correlate directly with spending for research and development.  Apple is often considered one of the most innovative companies in the world–but that is because it understood consumers and  how to create a new need,  rather than because it offers the most cutting edge technology, he said.  “Big company and big country advantages no longer hold, going forward.”

On a panel following the talk, Kiran Mazumdar-Shaw, founder and chair  of the Indian biotechnology company Biocon, said that the current process of biotechnology development is unsustainable and most products are too expensive to benefit most of those who need them.  “Countries in Asia must reinvent the process of drug innovation,” she said.

Greg Lucier, CEO of Life Technologies, which supplies systems, biological reagents and services to enable scientific research, said that  new genomics tools will be the stimulus to streamline innovation, cut costs,  and change the future of  human health.

Derek Hanekom,  South Africa’s Deputy Minister of Science and Technology emphasized the importance of  government’s role in providing access to care and sanitation. Governments can promote innovation by recognizing and supporting it,  reducing unnecessary regulations yet adding regulations to promote competition, and supporting  education to develop a skilled workforce.

Yucel Altunbasak, president of Tubitak, the Scientific and Technological Research Council of Turkey, listed financing, talented people, regulatory framework, and a governmental support mechanism as keys to helping emerging markets do “what the US did in the 1950’s.”

 

 

 

 

 




Companies Receive $1.3 M in MA-Israeli Collaboration Grants

Four Massachusetts-Israeli business collaborations have received a total of $1.3M in grant funding under the  Massachusetts-Israel Innovation Partnership (MIIP)–a  formal collaboration between the State of Israel and the Commonwealth of Massachusetts to encourage and support innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors.

The grants were announced yesterday at the  2012 BIO International Convention in Boston by Massachusetts  Governor Deval Patrick and  Israeli Chief Scientist Avi Hasson, of  MATIMOP, the  Israel Ministry of Industry, Trade and Labor.

The four winning projects are:

  • SBH Sciences (Natick) and Improdia (Israel) will work together toward the development and manufacture of a chronic inflammation-dependent immunosuppression prognostic kit. SBH will receive $184,000 from the Center and Improdia will receive $202,000 from Israel’s OCS.SBH Sciences is a discovery and preclinical contract research organization with expertise in production and analysis of cytokines and biomarkers. Improdia is a life science start-up focused on implementing novel biomarkers for immune system modulating therapies– using  simple blood tests for patients with chronic disease.
  •  Automated Medical Instruments (AMI – Needham) and STI Lasers (Israel) will develop new technology involving radio frequency energy to perform circumferential ablation of the pulmonary veins. AMI will receive $116,000 from the Center and STI Lasers will receive $110,000 from OCS. AMI is a start-up medical device company developing novel technology to perform atrial fibrillation treatment. STI Lasers is a medical device company specializing in laser cutting, micromachining and finishing of miniature metal components.“AMI is developing the CircumBlator™,  to offer a reliable and curative, minimally invasive treatment for millions of patients with atrial fibrillation, a disease that causes over 20 percent of strokes and untold misery,” said Martin Sklar, President and CEO of Automated Medical Instruments.
  • Lantheus Medical Imaging, Inc. (North Billerica) and Check-Cap (Israel) will  develop a novel 3-D imaging capsule that can be used to screen for polyps and lesions associated with colorectal cancer. Lantheus will receive $300,000 from MTC and Check-Cap has been selected to receive at least an equal amount from OCS. Lantheus  develops, manufactures and distributes innovative diagnostic imaging agents. Check Cap is a medical device company located in Mount Carmel, Israel with a “breakthrough” solution for Colorectal Cancer Screening.  “As a global leader in diagnostic imaging, Lantheus is dedicated to providing physicians with breakthrough new tools to enhance patient care. Teaming up with Check-Cap to develop and manufacture a cutting-edge imaging capsule further advances this ongoing commitment,” said Don Kiepert, President and CEO, Lantheus Medical Imaging.
  • FloDesign Sonics (Wilbraham) and Transbiodiesel (Israel)  will use FloDesign’s acoustic molecule separation technology to separate oil that can be used to create fuel from Transbiodiesel’s oil-generating algae. FloDesign Sonics will receive $55,000 from MassCEC and Transbiodiesel will receive $20,958 from OCS. FloDesign Sonics uses a novel ultrasonic acoustophoretic separation technology developed at Western New England University for a more efficient approach to wastewater treatment and micro-algae harvesting for biofuels. Transbiodiesel is a start- up company with a novel technology for producing biodiesel fuels from a variety of oils

The MIIP program was first announced in June 2011 at the BIO International Convention in Washington, D.C. and the first joint solicitation for proposals was launched in September 2011 by MATIMOP on the Israeli side and by the three participating Massachusetts agencies: the Massachusetts Life Sciences Center, the Massachusetts Technology Collaborative (MTC) and the Massachusetts Clean Energy Center (MassCEC). Total funding for the current projects is approximately $3m.

The partnership came as a result of a 2011 trade mission in which  Governor Patrick and a coalition of Massachusetts business executives and senior government officials explored growth opportunities of common interest for Massachusetts’ and Israel’s innovation industries. During that mission Governor Patrick and Shalom Simhon, Israeli Minister of Industry, Trade and Labor, signing on behalf of their respective states, signed a Memorandum of Understanding (MOU) in Jerusalem. MIIP was established to implement the MOU’s framework.

Massachusetts is the first U.S. state to establish a significant industrial R&D program with the State of Israel, according to a press release issued yesterday by Patrick’s office.

Today there are nearly 100 companies with Israeli founders or Israeli-licensed technologies in Massachusetts, according to the release.  In 2009, these companies employed nearly 6,000 people and generated $2.4 billion in direct revenue for the state. Local firms exported over $180 million worth of goods to Israel in 2009. Home to 377 hospitals and 37,000 practicing physicians, Israel is an important market for health-related technologies.

The New England-Israel Business Council, the US-Israel Science and Technology Foundation, the Government of Israel Economic Mission to North America, the Consulate General of Israel to New England and MOITI have all played an important role in promoting the program, according to the release.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

 




Picketers greet 15,000 participants at BIO 2012 Convention in Boston




AC Immune/Genentech to Partner on R&D for Alzheimer’s Antibody; $418M Agree’t

PRESS RELEASE

· New antibody program targets Tau protein, a major cause of Alzheimer’s disease

· License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)

Lausanne, Switzerland, 18 June, 2012 – AC Immune SA, today announced that it has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases.

Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments totaling more than Swiss Francs 400 million (approximately USD 418 million*) for Alzheimer´s disease and other indications. Additionally, AC Immune is eligible to receive royalties on net sales of products resulting from the collaboration. Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. Genentech will have global responsibility for pre-clinical and clinical development, manufacturing and commercialization of antibodies resulting from the collaboration.

Prof. Andrea Pfeifer, CEO of AC Immune said: “We are delighted to continue our excellent relationship with Genentech through this second landmark deal to fight Alzheimer’s disease. This underlines Genentech’s trust in AC Immune’s proprietary technology platform and we are confident in our joint abilities to develop not only
first-in-class but also best-in-class medication for one of the biggest healthcare problems of this century.”

“This second licensing deal gives us financial security to continue AC Immune’s
world-leading efforts to develop disease modifying therapies and diagnostics. We are now recognized as having one of the broadest and most advanced Alzheimer’s pipelines in the industry”, remarked Martin Velasco, Chairman of The Board of AC Immune .

Commenting on the deal, James Sabry, Genentech’s Vice President of Partnering , said: “Genentech is committed to bringing innovative treatments to patients suffering from devastating neurodegenerative diseases, and is developing a number of approaches to tackle Alzheimer’s disease. The addition of this anti-Tau program to our CNS pipeline complements other approaches we are investigating, including crenezumab which we in-licensed from AC Immune in 2006.”

About the anti-Tau Program

The Tau protein forms twisted fibers inside brain cells and build tangles that are considered by many in the scientific community as the second major cause of Alzheimer’s disease besides Abeta-plaques. The anti-Tau antibodies were discovered and humanized by AC Immune through its proprietary SupraAntigen TM technology.

“The anti-tau-antibodies have proven highly specific to misfolded Tau in relevant animal models for Alzheimer’s disease and are therefore well suited to be developed as a disease-modifying drug. This has significant potential as there are at present no known cures for Alzheimer’s disease,” said Dr. Andreas Muhs, Chief Scientific Officer
of AC Immune .

About Crenezumab

An anti-Abeta antibody, crenezumab was discovered and humanized by AC Immune. It is designed to bind to amyloid beta (Abeta), the main constituent of amyloid plaque in the brains of patients with Alzheimer’s disease. Abeta is considered to be a major cause in the development of the disease. Genentech is currently evaluating crenezumab in a Phase II clinical study in Alzheimer’s patients with mild to moderate symptoms. At the time the deal with Genentech was announced in December 2006, it was stated to have a potential total value of more than USD 300 million in clinical and regulatory milestone payments to AC Immune, excluding royalties.

In May 2012, crenezumab was selected to be tested in the world’s first-ever prevention trial in healthy individuals who are genetically destined to develop Alzheimer’s disease. This landmark study to investigate whether an anti-amyloid treatment can stave off the disease is being run by the US National Institutes of Health (NIH), the Banner Alzheimer’s Institute (BAI), the University of Antioquia in Colombia and Genentech.

About Alzheimer’s Disease

Alzheimer´s is the most common form of dementia. It is degenerative, irreversible and terminal. The memory and thinki ng of the patients is progressively destroyed. Besides the personal aspect there is a huge social and economic impact. Alzheimer´s disease is recognized as a significant health crisis of the 21st century with currently more than
36 million patients worldwide. This number is expected to double in the next 20 years and to triple to more than 116 million by 2050. In 2010 global worldwide costs were estimated to be USD 604 billion and were exceeding 1% of the global domestic product (Reference: World Alzheimer Report 2011, Alzheimer’s Disease International).

Scientists don’t yet fully understand what causes Alzheimer’s disease, but it has become increasingly clear that it develops because of a complex series of events that take place in the brain over a long period of time. Two proteins – Tau and Abeta – are perceived as the major causes of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells, while plaques and oligomers formed by Abeta occur outside the brain cells of people with Alzheimer’s disease.

About AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development. The company continues to develop in house the small molecule ACI-91 and the vaccine ACI-24 in Phase II and Phase I/IIa clinical development respectively. These three clinical programs are focused on Alzheimer’s disease, and are backed by a rich portfolio of preclinical compounds. The therapeutic molecules are also leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma. Since its foundation in 2003, AC Immune has raised CHF 64 million from private investors.

 

-Anita M. Harris
Disclosure: I will be working with AC Immune at the Biotechnology Industry Organization today in Boston.

 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.




International & MA Cancer R&D Clusters Showcased at Whitehead Institute

Four Boston-area startups were among those showcased  in an international program on collaborative cancer research & therapy clusters held today at the Whitehead Institute in Kendall Square, Cambridge.

All four of the Boston companies are developing methods and technologies that aim to better diagnose or cure cancer; all are hopeful; all are seeking funding, investors, or purchasers.

The program, called the International Cancer Cluster Showcase,  was sponsored by Sanofi, which recently purchased Cambridge-based Genzyme  Corporation, and by cancer  research and treatment clusters in the Norway, the UK, France and  in Massachusetts.

The program was held in conjunction with the International Biotechnology Industry Organization (BIO) Convention, to start tomorrow.

In introducing the Boston area companies, Abigail Barrow of the Massachusetts Technology Transfer Center,  who chaired  the Boston and the overall sessions,  pointed out that Cambridge is, perhaps, the paramount biotechnology and cancer research center in the US.

  • AcuityBio, Inc. a Boston University Spinoff,  is developing a  biodegradable polymer mesh  to be implanted during cancer surgery for later, sustained use in local administration of cancer drugs, according to John Schwartz, the AcuitBio CEO.  The goal is to  prevent cancer recurrences in specific soft tissues thus improving the quality of patients’ lives, recucing the cost of care, increasing the length of disease-free progression and sigificantly improving cure rates for early stage cancer patients,  Schwartz said.
  • Joel Beriac, PhD, the president & CEO of Akrivis Technologies said that his company is developing an ultrasensitive ” Z-Tect,” (TM) technology platform that promises to allow much earlier cancer detection and more effective personalized therapies than is currently possible. Z-tect will save numerous lives and reduce healthcare costs by lowering “several thousand fold” the current limit-of-detection of early cancer biomarkers, imaging much smaller cancer lesions. Akrivis plans to ultimately develop, beyond ultrasenstivie diagnostics, safer and more efficacious targeted therapies.
  • BIOARRAY Therapeutics  is developing molecular diagnostics to improve cancer treatment decisions that are currently made on a trial-and-error basis, according to  Marcia V. Fournier, PhD, the BIOARRAY founder and CEO.  BIOARRAY’s core technology identifies relevant cancer biomarkers based on the normal biology and micro-environment representing underlying biological processes involved in the progression of tumors– independent of any specific patient set, cancer subgroup or treatment, Fournier said. The company’s lead diagnostic is a response prediction test for breast cancer–targeting the growing molecular diagnostics and personalized medicine markets.
  • CanThera Therapeutics is a development stage oncology therapeutics company built on technology from the Mass General Hospital laboratories and the Broad Institute.  According consultant Peter Leone, the investigators have found that a natural substance, piperlongumine (PL) appears to kill cancer cells by jamming the machinery that dissipates high oxidative stress (ROS). Normal cells have low levels of ROS and don’t need high levels of the antioxidant enzymes that PL stymies. CanThera aims to advance a selected novel analog of PL into the clinic in 2012.

The showcase also featured:


QUEBEC PRESENTERS:

Q-CROC (Quebec – Clinical Research Organization in Cancer)    http://qcroc.ca      

 

OSLO PRESENTERS:

 

TOULOUSE/CANCER BIO SANTE CLUSTER PRESENTERS

 

UK PRESENTERS

  • Acublate  Limited

 


Poster Session Companies

Oncocat: www.oncocat.org/principal.php?idiom=eng

AB-therapeutics: www.ab-therapeutics.com

Oryzon: www.oryzon.com/es/inicio 

 

–Anita M. Harris

 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

 

 

 

 

 




UK Life Science Consulting Firm Alacrita To Open US HQ in Cambridge, MA

UK-based Alacrita, a global life science consulting firm with consultants worldwide, will soon be opening an office in Cambridge, MA, according to Robert Johnson, who will head the office, here.

The company was co-founded two years ago by Anthony Walker, who had previously served as Executive Director of Global External R&D Europe at Eli Lilly,  and  by Johnson, who had led business development at Onyvax, a biotech company that developed biopharmaceuticals to combat cancer.

Drawing on the capabilities of more than 50 consultants worldwide, Alacrita  provides strategic, operational,  technical  advice or  hands-on project management to organizations of all sizes in  the pharma, biotechnology and life science industries, Johnson said.

According to the Alacrita Web site, clients may be academic institutes, tech transfer experts,  life science investors, startups  or  established companies in need of expertise in:

  • Business development and marketing
  • Intellectual property
  • Product development
  • Regulatory affairs

Recent whitepapers available on the  company Website   include:

Alacrita’s US offices will be located in the Cambridge Innovation Center in Kendall Square.  The company name comes from the Latin, “alacritas,” or “lively.”  It is meant to convey “a cheerful readiness,” Johnson said.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

 

 




Pasteur Institute Spin-out Ariana Pharma Opens Cambridge Office; Analytics Tech to Streamline Clinical Trials

SHANAHAN NAMED VP OF BUSINESS DEVELOPMENT

—One of the newest international companies to expand into Cambridge is Ariana (R)  Pharma–a 2003 spin-out of the Pasteur Institute in Paris.  Its  subsidiary, Ariana Data Intelligence, Inc., located in the Cambridge Innovation Center at 1 Broadway,  will provide novel non-statistical clinical data analysis technology to pharma and the FDA,  Ariana announced today.

The technology,  “Knowledge Extraction and Management Technology (KEM)” is aimed at reducing cost, bias, and risk in clinical trials.

“The US pharma and biotech markets tend  to be early technology adopters and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said  Dr. Mohammad Afshar, Ariana’s President and CEO.

KEM   “is the only FDA-tested technology that  can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials,” Afshar said.

A “unique” association rules-based (non-statistical) analytical technology, KEM  finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect, according to Afshar.  KEM thus optimizes clinical trial inclusion/exclusion criteria, thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and cash, and reducing clinical drug development risk.

In conjunction with the opening, Ariana has appointed James M. Shanahan as Vice President  of Business Development.  Shanahan was previously a co-founder and is currently a  board member of SynDevRx, Inc., an oncology-focused biotech company. He was also a co-founder and VP Corporate Development of JAM Technologies, Inc.

Ariana offers something “special and desperately needed “by the pharmaceutical industry, Shanahan said.   “Companies spend tens of millions generating data.  Now, it’s all about making sense of that data.  KEM identifies useful, complex biological relationships that statistics routinely miss.”

More information is available at  http://www.arianapharma.com/  .

–Anita M. Harris

 




Healthbox expands to Cambridge; $50K health tech startup competition deadline is June 24.

Chicago-based  Healthbox is now accepting applications for a new,  $50,000 three-month  health tech business accelerator program  to start August 13,  in Cambridge.

In the program, up to ten  selected New England-based companies will receive: $50,000 in seed capital;  collaborative workspace;  access to a mentor network of industry experts  and strategic guidance, according to Dan Phillips, a director of  Sandbox Industries, Healthbox’ parent company, who attended Venture Cafe in the Cambridge Innovation Center last week.  The  program will conclude with a high-profile conference in November at which each participant will pitch to an audience of investors and healthcare leaders from across the country.

Healthbox  is one of the first business accelerator programs in the healthcare industry to support a platform for  innovation among seed-stage companies, according to the Sandbox Website.

“Massachusetts’ world-renowned academic institutions, cutting-edge provider systems and strong investor community make it an ideal location for a healthcare accelerator to stimulate the ecosystem and support new ideas,” said Healthbox founder Nina Sharif, in a press release.  “We are looking forward to working with New England’s most promising healthcare entrepreneurs to help them gain traction in the industry and develop sustainable businesses.”

Massachusetts Blue Cross Blue Shield Venture Funds will be among those providing financial support for the Cambridge program, according to Ryan Boxill of the BCBSMA Finance Development Program.

Earlier this year, Healthbox hosted its first program in Chicago.  According to a company press release, ten healthcare technology startups were selected from hundreds of applicants and, within three months,  the teams were able to evolve their business models and establish new partnerships and pilots. The program was supported by strategic partners including  Boston-based HLM Venture Partners; Ascension Health;  BlueCross BlueShield Venture Partners; California HealthCare Foundation; Merge Healthcare;  Merrick Ventures; Sandbox Industries and Walgreens.

David Nichols of CareWire, a Minnesota-based company that participated in the Healthbox Chicago program said: “This program has helped us really focus in on our core value, rapidly test assumptions and launch pilots with new customers.”

Mark Hall, the CEO of New Jersey-based United Preference, another Healthbox Chicago participant, added “Things that take 6 months or 12 months in other environments, we’ve been able to achieve in 2 to 4 weeks here.”

According to its Website, Sandbox Industries creates, invests  in and explores new businesses that it believes could change markets. Through a new model of business development that “helps rather than harass entrepreneurs,”  it aims  to “grow successful companies through collaboration and knowledge sharing…redefining the way great ideas are generated and transformed into successful companies.”

Applications are currently being accepted on the Healthbox website at www.healthboxaccelerator.com/apply. For information and announcements about the program, visit www.healthboxaccelerator.com and follow the Twitter feed – @health_box

—Anita M. Harris

Anita Harris is a writer and journalist based at the Cambridge Innovation Center in Kendall Square, Cambridge.